Skip to content
Monday 10 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,862.50
-0.35%
DAX
26,323.88
+0.02%
CAC 40
8,726.03
+0.13%
STOXX 50
6,535.62
+0.18%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Tuesday 16 March 2021 1:52 pm  |  Updated:  Wednesday 17 March 2021 9:48 am

EU medicines regulator: ‘No indication’ Astrazeneca vaccine causes blood clots

By: Poppy Wood

Add as a preferred source on Google

The EU’s medicines regulator has insisted there is “no indication” that Astrazeneca’s Covid vaccine causes blood clots among patients, after a swathe of European countries suspended the jab over safety concerns.

Emer Cooke, executive director of the European Medicines Agency (EMA), said the agency remains “firmly convinced” that the benefits of the Astrazeneca vaccine outweigh the risk of side-effects. 

Cooke added there were no signs to suggest that the estimated 17m Astrazeneneca vaccinations delivered across Europe have caused reported cases of blood clots.

“We know that many thousands of people develop thousands of clots annually for many different reasons”, she said, adding that the number of thromboembolic was the normal level among the general European population. 

News of the EMA’s continuing support appeared to calm investor nerves, with Astrazeneca shares up 3.2 per cent to 7,199.2p at market close.

It comes as Sweden this morning joined a list of 15 countries across Europe that have temporarily banned the jab following reports of blood clot-related deaths.

No such cases have been reported in Sweden but neighbouring Norway and Denmark have each reported one death.

France, Italy and Germany yesterday announced a temporary suspension of the jab while the EMA investigation is underway.

Read more

Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

The EMA said on Friday there was no evidence of a link between the events and the jabs, stressing that “the vaccine’s benefits currently still outweigh the risks”. It urged countries to continue with their vaccination campaigns.

It will meet today to discuss the continued use of the jab across Europe, with a decision set to be announced on Thursday.

The World Health Organisation (WHO) has urged countries to continue using the vaccine as investigations into the reports continue.

UK leaders and medical professionals have united to insist on the jab’s safety, as Britain continues to prioritise the vaccine in its rapid immunisation programme.

The Prime Minister reiterated his support for the Astrazeneca vaccine on a visit to Coventry yesterday, insisting he was “very confident” it was safe and effective.

Dominic Raab, the UK’s foreign secretary, said it was “crystal clear” that the vaccine was safe and effective, pointing to support from regulators in Britain and the EU.

He told BBC Breakfast this morning: “There is no extra risk on the evidence that we’ve seen, which is why they have authorised the vaccine and haven’t taken any further action.

“We respect the process and procedures that some other countries may need to go through but the vaccine is safe and people should certainly continue to take it and to protect themselves and their friends and family.”

Read more

Clinigen Appoints Greg Skalicky as Chief Executive Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Politics

Related Topics

  • AstraZeneca
  • Coronavirus
  • Re-lockdown
  • Vaccine

Trending Articles

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Thames Water faces fresh threat to survival after pensions regulation breach

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

More from Morning Wire

  • Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

    Business Wire
  • Clinigen Appoints Greg Skalicky as Chief Executive Officer

    Business Wire
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

    Business Wire
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook